Viewing nowCombinationGlycitamet Tablet 50/500 Milligrams
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 202204580 · Approved 2022.12.21 · Insurance code 657308820
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication, administered alongside a diet and exercise regimen, helps improve blood sugar control in patients with type 2 diabetes. The combination of sitagliptin and metformin effectively aids in blood sugar management. Therefore, it improves blood sugar levels and facilitates diabetes management, enhancing overall health.
For antidiabetic therapy, the dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients in whom this medication is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may begin at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medication should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients in whom this medication is contraindicated).
This medication is composed of two ingredients, sitagliptin and metformin, primarily used for the treatment of type 2 diabetes. While taking this medication, there is a possibility of a rare but serious allergic reaction, so if symptoms such as skin rashes, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a physician. Additionally, there is a risk of acute pancreatitis, which is inflammation of the pancreas, so in the event of symptoms like abdominal pain, nausea, or vomiting, inform your healthcare provider promptly. This medication should not be administered to patients with reduced kidney function, especially in cases of moderate to severe renal impairment. Before and after tests involving iodine-based contrast agents, this medication should be temporarily discontinued, and it should only be resumed after confirming normal kidney function. It is advisable for pregnant or potentially pregnant women and nursing mothers to avoid taking this medication. When taking this medication, it is essential to be cautious of signs of hypoglycemia, particularly if taken concurrently with insulin or sulfonylureas, as the risk of hypoglycemia may increase, making regular blood sugar level checks important. This medication should also be avoided in patients with impaired liver function, and regular liver and kidney function tests are recommended. Lactic acidosis, a rare but life-threatening side effect, can occur; therefore, if symptoms such as muscle pain, fatigue, difficulty breathing, or abdominal pain arise, contact a healthcare provider immediately. Alcohol consumption may increase the risk of side effects associated with this medication, so it is recommended to avoid drinking alcohol while on this medication. Furthermore, this medication should be temporarily discontinued if serious infections, dehydration, congestive heart failure, acute myocardial infarction, or other severe diseases occur, and it is necessary to interrupt its use for a certain period before and after surgery. Elderly patients are at greater risk of decreased kidney function, hence increased caution is required, along with regular kidney function monitoring. This medication is not recommended for use in children under 18 years of age, as its safety and efficacy have not been sufficiently proven. Lastly, if other medications are being taken along with this medication, interactions may occur, so it is important to inform the healthcare provider of all medications being taken and to monitor closely.
anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, severe and disability-associated arthralgia, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dyspnea, unstable angina, dizziness, acute renal failure, reduced appetite, itching, constipation, dermatitis, weight loss
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air entry, and it is best kept at room temperature between 1°C and 30°C. This way of storage can help maintain the medication's effectiveness over time.
Light pink oval film-coated tablets
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.